<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036019</url>
  </required_header>
  <id_info>
    <org_study_id>05/03-04-009</org_study_id>
    <nct_id>NCT04036019</nct_id>
  </id_info>
  <brief_title>A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy</brief_title>
  <official_title>A Study Evaluating Safety and Efficacy of CD20 CAR-T(C-CAR066) in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Tongji Hospital, Tongji University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single arm, single-center, non-randomized clinical study which is designed to&#xD;
      evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received&#xD;
      CD19 CAR-T therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to enroll 12 patients to assess the safety and efficacy of C-CAR066.&#xD;
      Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection.&#xD;
&#xD;
      The study will include the following sequential phases: Screening, Pre- Treatment (Cell&#xD;
      Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence and severity of Treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12weeks, 6months, 12 months</time_frame>
    <description>Lugano criteria(NHL,2014).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>12weeks, 6months, 12months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>C-CAR066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous C-CAR066 administered by intravenous (IV) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD20-directed CAR-T cells</intervention_name>
    <description>Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously</description>
    <arm_group_label>C-CAR066</arm_group_label>
    <other_name>C-CAR066</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteered to participate in this study and signed informed consent&#xD;
&#xD;
          2. Age 14-70 years old, male or female&#xD;
&#xD;
          3. Patients with CD20+ DLBCL(including PMBL and according to the NCCN. non Hodgkin's&#xD;
             lymphoma Guidelines(2019 version1.0) , at least one measurable lesion(LDi≥ 1.5 cm);&#xD;
&#xD;
          4. r/r patients who received prior CD19 CAR-T therapy；&#xD;
&#xD;
          5. At least one week from the end of treatment regimen (radiation, chemotherapy, mAb,&#xD;
             etc) to apheresis;&#xD;
&#xD;
          6. No immunosuppressive therapy was used within 1 week before infusion, including but not&#xD;
             limited to systemic therapy;&#xD;
&#xD;
          7. No mAb treatment within 2 weeks before infusion&#xD;
&#xD;
          8. LVEF≥ 50% (UCG)&#xD;
&#xD;
          9. No active pulmonary infections, normal pulmonary function and SpO2≥92%&#xD;
&#xD;
         10. No contraindications of apheresis;&#xD;
&#xD;
         11. Expected survival ≥ 3months&#xD;
&#xD;
         12. ECOG score 0 or 1&#xD;
&#xD;
         13. The apheresis was received by laboratory and met the requirements for manufacturing&#xD;
             CAR-T cell&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history of allergy to cellular products&#xD;
&#xD;
          2. Laboratory criteria: Serum total bilirubin ≥2mg/dl, albumin≤35g/L, AST and ALT ≥5 x&#xD;
             ULN, Creatinine≥2.0mg/dl, ANC≤750/uL, Platelets≤ 50x10^9/L&#xD;
&#xD;
          3. Have a hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman&#xD;
             syndrome ,etc;&#xD;
&#xD;
          4. According to the NYHA cardiac function grading standards, patients with grade III or&#xD;
             IV cardiac dysfunction；&#xD;
&#xD;
          5. A history of QT prolongation&#xD;
&#xD;
          6. Patients with central nervous system involvement&#xD;
&#xD;
          7. Severe active infections (except for simple urinary tract infections, bacterial&#xD;
             pharyngitis), or currently undergoing intravenous infusion of antibiotics, or&#xD;
             intravenous infusion of antibiotics within 1 week prior to cell infusion. However,&#xD;
             prophylactic antibiotic, antiviral and antifungal infection treatments are&#xD;
             permissible;&#xD;
&#xD;
          8. People infected with HIV, HBV, HCV and TPPA/RPR, and carriers with HBV;&#xD;
&#xD;
          9. Subjects who are not sterilized have any of the following conditions:&#xD;
&#xD;
               1. are pregnant/lactating; or&#xD;
&#xD;
               2. planned pregnancy during the trial; or&#xD;
&#xD;
               3. being fertile and unable to use effective contraception；&#xD;
&#xD;
         10. The investigators consider that the subject has other conditions that are not suitable&#xD;
             for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aibin Liang, MD,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aibin Liang, MD,Ph.D.</last_name>
    <phone>0086-021-66111019</phone>
    <email>lab7182@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Li, MD,Ph.D.</last_name>
    <phone>0086-021-66111015</phone>
    <email>lilyforever76@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital, Tongji University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aibin Liang, MD,Ph.D.</last_name>
      <phone>0086-021-66111019</phone>
      <email>lab7182@tongji.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</investigator_affiliation>
    <investigator_full_name>Aibin Liang，MD，Ph.D.</investigator_full_name>
    <investigator_title>Director，Department of Hematology</investigator_title>
  </responsible_party>
  <keyword>B cell lymphoma received prior CD19 CAR-T therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

